The DKK1 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human gastric adenocarcinoma AGS cell line, designed for targeted disruption of the DKK1 gene. This product provides a loss-of-function model to investigate the roles of the DKK1 protein in Wnt/??-catenin and CKAP4/PI3K/AKT signaling cascades. The polyclonal nature ensures heterogeneous gene disruption, enabling robust population-level analysis of DKK1 deficiency without clonal selection artifacts. Researchers can utilize these cells to examine how DKK1 ablation modulates downstream pathway activities, gene expression profiles, and phenotypic behaviors relevant to gastric cancer biology.
The AGS host cell line originates from a human gastric adenocarcinoma and is widely employed as an epithelial cancer model for dissecting signaling mechanisms governing proliferation, migration, and metastasis. Gastric cancer remains a leading cause of cancer-related mortality, and AGS cells recapitulate key molecular features of aggressive disease, including aberrant Wnt pathway activation and dysregulated PI3K/AKT signaling. Their well-characterized genetic background and established culture protocols make them an ideal chassis for CRISPR/Cas9-mediated genome editing, allowing systematic interrogation of tumor suppressor and oncogenic pathways in a physiopathologically relevant gastric environment.
DKK1 functions as a secreted antagonist of canonical Wnt/??-catenin signaling by binding the co-receptors LRP5 and LRP6 in conjunction with KREMEN1 or KREMEN2, thereby promoting internalization of the Wnt receptor complex and preventing ??-catenin nuclear accumulation. In addition, DKK1 can interact with CKAP4 to initiate PI3K/AKT signaling independently of LRP5/6, highlighting a bifurcated mechanism of action. Upstream regulators of DKK1 include TP53, the ??-catenin/TCF complex, WNT3A, and BMP4, while its downstream targets encompass ??-catenin itself, MYC, CCND1, AXIN2, and MMP7. In gastric cancer, loss or overexpression of DKK1 perturbs this network, altering tumor progression through both Wnt-dependent and CKAP4/PI3K/AKT-dependent axes.
Disruption of DKK1 in AGS cells offers a powerful tool to disentangle the dual role of this secreted factor in gastric carcinogenesis. Depending on the cellular context, DKK1 can act as a tumor suppressor by restraining Wnt-driven proliferation or as a tumor promoter via CKAP4-mediated activation of PI3K/AKT survival signals. This polyclonal knockout model allows systematic analysis of outcomes such as ??-catenin stabilization, transcriptional activation of Wnt target genes, phosphorylation of AKT, and changes in cell migration and invasion. Such studies are essential for clarifying the paradoxical behaviors of DKK1 and for evaluating its potential as a therapeutic target or prognostic biomarker in gastric and other cancers.
Typical research applications include functional dissection of Wnt/??-catenin and PI3K/AKT crosstalk using western blotting for ??-catenin and phospho-LRP6, TOPFlash luciferase reporter assays, RT-qPCR for MYC and AXIN2 expression, and immunofluorescence to monitor ??-catenin localization. Co-immunoprecipitation can be performed to assess DKK1-LRP6 interaction in rescue experiments, while transwell migration and invasion assays, apoptosis assays, and MTT proliferation assays quantify phenotypic consequences of DKK1 loss. RNA-seq enables transcriptome-wide exploration of DKK1-dependent gene networks. These polyclonal knockout cells are suitable for drug resistance studies, metastasis research, and biomarker discovery campaigns. For additional technical specifications or ordering information, please contact Ascent Research.
